Please login to the form below
Combination treatment
This page shows the latest Combination treatment news and features for those working in and with pharma, biotech and healthcare.
MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
The results show that the Lynparza combination therapy significantly improved radiographic progression-free survival. ... the combination treatment was similar to that of earlier clinical trials.
Latest news
-
Eli Lilly’s Verzenios recommended by NICE as combination therapy for early-stage breast cancer
The trial showed that adjuvant treatment using Verzenios in combination with endocrine therapy decreased the risk of breast cancer recurrence by 32%. ... The availability of the combination treatment on the NHS is supported by interim funding from the
-
Roche’s Polivy receives EC approval for lymphoma therapy
The combination therapy is for patients with previously untreated diffuse large B-cell lymphoma. ... While many patients are initially responsive to treatment, four out of ten are not cured with the existing standard of care.
-
AstraZeneca’s Imfinzi plus chemotherapy accepted for Priority Review in the US
AstraZeneca’s (AZ) has announced that its treatment, Imfinzi (durvalumab), in combination with chemotherapy, has been accepted and given a Priority Review in the US for patients with locally advanced or ... There was a significant 25% reduction in the
-
FDA approves BMS’s Opdualag for metastatic or unresectable melanoma
The new, first-in-class fixed-dose dual immunotherapy combination treatment is administered as a single intravenous infusion. ... Opdualag is a new, first-in-class, fixed-dose, dual immunotherapy combination treatment and is administered as a single
-
MHRA grants approval for AstraZeneca’s Evusheld in the UK
It is the first antibody combination treatment authorised for use before exposure to COVID-19 infection in order to prevent disease licensed in the UK. ... AstraZeneca (AZ) has announced that its antibody combination treatment Evusheld (tixagevimab
More from news
Approximately 0 fully matching, plus 324 partially matching documents found.
Latest Intelligence
-
As COVID-19 takes over the world, biopharma fights back
A combination HIV treatment: AbbVie’s Kaletra. In an unprecedented move, AbbVie has suspended its patents on its combination HIV drug Kaletra, after it was identified as having potential against ... The combination drug was first included in Chinese
-
Deal Watch April 2016
Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 85 . Dong A (SK). Tobira (US). Cross license. Evogliptin
-
Pharma deals in April 2015
No deal terms were disclosed. The initial development plan will look at the combination therapy as a potential treatment for NHL. ... The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid.
-
Pharma deals during July 2014
The acquisition of Almirall's respiratory business enhances AZ's respiratory franchise bringing a portfolio of marketed and developmental single and combination products for the treatment of asthma and COPD. ... tremelimumab. Existing partners
-
Interview: AstraZeneca's Susan Galbraith
And again, matching drugs that work well together will be crucial going forward: “Combination treatment will be a critical component; how best to put these drugs together with other checkpoint inhibitors, ... This includes people with NSCLC who have a
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
What does the future hold for Light-chain Amyloidosis?
approval in combination with CyBorD for the treatment of newly diagnosed adult patients with AL amyloidosis. ... Prior to the approval of a new combination treatment for use across Europe, we conducted the first wave of our research to generate a
-
Oncosec
body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; ... Results from recently completed
-
Marketing strategy in complex environments
The last few years have seen influential scientific advances, resulting in subtle shifts in how pharma tackles disease treatment. ... The treatment of aggressive diseases often benefits very noticeably from combination therapy, especially when involving
More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Live Webinar: Navigating the Nuances of Europe's MedTech Industry
- Why project managers are key to creating quality content
- Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- A creative awakening – how pharma is bringing innovation to the patient journey
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
